ClinicalTrials.gg

Urinary Bladder, Overactive clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 859 studies for Urinary Bladder, Overactive across more than 10 countries. 127 are recruiting or about to start. 711 of them are mainly about Urinary Bladder, Overactive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 945 studies for Urinary Bladder, Overactive. How that becomes 858 here

This page counts the studies the registry files under Urinary Bladder, Overactive, and those it files under no condition that list Urinary Bladder, Overactivethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 945Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −29List Urinary Bladder, Overactive as a condition, but the registry did not file them under itMost often written as “Overactive Bladder Syndrome” (22), “Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)” (1), and “Overactive Bladder With Symptoms of Frequency, Urgency, and Urge Urinary Incontinence” (1). The registry filed them under other conditions only, most often Urinary Incontinence, Urge (6) and Lower Urinary Tract Symptoms (4).
  3. −58Match it another way52 name it in the title, 3 in a keyword, and 3 by a synonym or other text the search reads.
  4. 858The count on this page56 of them list Urinary Bladder, Overactive in their own words; the registry filed them under no condition.

Status

Completed
520
Status unknown
100
Recruiting
75
Terminated
67
Not yet recruiting
43
Withdrawn
29

Phase

Phase 4
141
Phase 3
103
Phase 2
84
Phase 1
61
Early Phase 1
10

Where

United States
333
Turkey
67
Korea, Republic of
62
United Kingdom
57
Canada
57
France
53

Who develops what

Add Urinary Bladder, Overactive to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 4 programs from 3 companies, 4 with this as their studies’ main aim; 0 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
tolterodineRecent, limited
Evidence
  • NCT07780786 · ninamed pty ltd · Phase 3 · live · comparator · “tolterodine tartrate 4 mg extended release” · registered Aug 2026
  • NCT03583372 · Sumitomo Pharma Co., Ltd. · Phase 3 · comparator · “Tolterodine Tartrate ER” · registered Jun 2018
  • NCT03575702 · R-Pharm · Phase 3 · comparator · “Urotol®” · registered Jun 2018
  • NCT03492281 · Sumitomo Pharma Co., Ltd. · Phase 3 · comparator · “Tolterodine Tartrate ER” · registered Mar 2018
  • NCT02485067 · sk chemicals · Phase 3 · background · “Detrusitol 2mg tablet” · registered Jun 2015
Viatris Inc.45% of its industry studiesUS: off-patent, 12 generics marketed11 study
solifenacinRecent, limitedPhase 4 trial recorded
Evidence
  • NCT05282069 · Dong-A ST Co., Ltd. · Phase 3 · comparator · “Solifenacin 5mg” · registered Mar 2022
  • NCT03566134 · Dong-A ST Co., Ltd. · Phase 2 · comparator · “Solifenacin 5mg” · registered Jun 2018
  • NCT03106623 · Ono Pharmaceutical Co. Ltd · Phase 2 · comparator · “solifenacin succinate + mirabegron” · registered Mar 2017
  • NCT01767519 · AbbVie · Phase 3 · comparator · “solifenacin” · registered Jan 2013
Astellas Pharma Inc86% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 4 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Sep 2027 est.NT 201 200U and Vibe System, NT 201 300U and Vibe System · Vensica Therapeutics Ltd. · Phase 2 main aimNCT07553065 RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder — primary endpoint: Mean daily urinary incontinence · 210 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Urinary Bladder, Overactive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimuscarinics 6 open · Beta-3 agonists 6 open · Estrogens 2 open · PDE5 inhibitors 1 open · NK1 receptor antagonists 3

Coming up

49studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger. 7 (9%) take children under 18. 39 (52%) are for women only and 1 (1%) for men only; 8 (11%) take healthy volunteers.

Recruiting studies that take each age, of 75
AgeWomenMen
107 (9%)7 (9%)
1847 (63%)27 (36%)
3062 (83%)30 (40%)
4064 (85%)30 (40%)
5066 (88%)30 (40%)
6566 (88%)30 (40%)
7561 (81%)26 (35%)
8554 (72%)25 (33%)

Across all 859 studies, recruiting or not: 20% stop at 75 or younger and 14% at 65; 10% take children; 41% are for women only and 6% for men only; 18% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Urinary Bladder, Overactive studies take

Of 55 phase 4 interventional studies under Urinary Bladder, Overactive, half reached primary completion within 23 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 19 mo4–22 · 30 studies6 mo4–11 · 20 studies—
Phase 217 mo11–22 · 22 studies——
Phase 318 mo11–34 · 33 studies16 mo11–24 · 26 studies—
Phase 423 mo15–48 · 55 studies—29 mo18–51 · 43 studies
Interventional, no phase19 mo10–40 · 175 studies13 mo8–25 · 41 studies22 mo11–40 · 134 studies
Observational32 mo17–45 · 59 studies—35 mo17–50 · 46 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 859. Browse all 859 → or search them.